Wilms Tumor in Northern Europe

What's on this Page:

Explore Wilms tumor statistics, stage distribution, survival, mortality, treatment systems and research networks across Northern Europe. This page examines how national pediatric oncology services, SIOP–RTSG, CCLG, NOPHO and European reference networks coordinate childhood kidney cancer care throughout the region.

Northern European Wilms tumor incidence and estimated annual cases.
Regional stage distribution, survival and mortality indicators.
Treatment protocols and specialist pediatric oncology systems.
SIOP–RTSG, CCLG, NOPHO and European research networks.
WCF’s GWTI and country resources for Northern Europe.

Frequently Asked Questions (FAQ's);
Learn More & Get Support.

Go to Guide

Northern Europe & Wilms Tumor

Northern Europe includes several highly developed paediatric oncology systems supported by specialist childhood cancer centres, national cancer registries, multidisciplinary clinical teams and extensive participation in international Wilms tumor research. Although each country operates its own healthcare and referral system, centres across the region collaborate through SIOP-RTSG studies, European clinical networks and cross-border initiatives such as ERN PaedCan.

For the purposes of this website, Northern Europe follows the geographical classification used by the United Nations Statistics Division. This definition provides a consistent framework for organising regional Wilms tumor statistics, survival outcomes, treatment-system information and country-specific educational resources.

Under the United Nations M49 geographic classification, Northern Europe includes:

Denmark
Estonia
Finland
Iceland
Ireland
Latvia
Lithuania
Norway
Sweden
United Kingdom

These countries do not operate through one regional healthcare authority. Pediatric oncology care is organized through national health systems, specialist childhood cancer centres, national clinical networks and international research groups.

Northern Europe includes the publicly funded national health services of the United Kingdom and Ireland, highly integrated Nordic healthcare and registry systems, and the developing national and cross-border pediatric oncology networks of the Baltic states.

Although the region generally records strong Wilms tumor survival, differences remain in:

Population size.
Number and distribution of specialist centres.
Travel distances.
Clinical-trial availability.
Central pathology and radiology review.
Survivorship services.
Cross-border access to rare-tumor expertise.
Cancer-registry coverage.
Availability of published national data.

WCF’s first dedicated Northern European country page focuses on the United Kingdom. Further pages for Ireland, the Nordic countries and the Baltic states can be introduced through WCF’s Global Wilms Tumor Initiative™.

Wilms Tumor Incidence in Northern Europe

European population-based registry research reported approximately 8.8 malignant renal tumors per million children under 15 each year. Wilms tumor accounted for approximately 93% of those tumors, and around 7% were bilateral. European ACCIS renal-tumor study

A later international analysis of 15,320 malignant renal tumors in children, reported by 163 cancer registries, found childhood renal-tumor incidence of approximately 9–10 cases per million children in Europe and North America. International childhood renal-tumor incidence study

Applying these incidence benchmarks to Northern Europe’s combined child population suggests approximately:

150–170 malignant childhood renal tumors annually
Approximately 140–160 Wilms tumor diagnoses annually

These are WCF modelled planning estimates rather than confirmed regional registry totals. The figures should be updated when comparable contemporary data covering all ten Northern European countries become available.

The United Kingdom alone records an average of approximately 83 childhood Wilms tumor diagnoses annually. UK and Ireland IMPORT study

Northern European statistical overview

IndicatorPublished evidence or estimate

European childhood renal-tumor incidence8.8 per million annually

Wider European incidence rangeApproximately 9–10 per million

Proportion represented by Wilms tumorApproximately 93%

Historical proportion with bilateral diseaseApproximately 7%

Recent UK/Ireland bilateral disease8%

Modelled Northern European Wilms tumor casesApproximately 140–160 annually

Average UK Wilms tumor diagnosesApproximately 83 annually

Historical Northern European five-year survival91%

Recent UK/Ireland five-year overall survival92.5%

Reported incidence is affected by diagnostic availability and cancer-registry completeness. Stronger registration may produce higher recorded incidence because more cases are accurately identified and reported.

Wilms Tumor Survival in Northern Europe

Northern Europe has historically reported some of Europe’s strongest childhood Wilms tumor outcomes.

A European study of more than 5,000 malignant childhood renal tumors reported five-year Wilms tumor survival of approximately:

85% across Europe for children diagnosed during 1988–1997.
91% in Northern Europe during the same period.
87% across Europe for children diagnosed during 1993–1997, compared with 73% during 1978–1982.

These historical findings demonstrate the improvement associated with standardized chemotherapy, specialist surgery, radiation therapy when required and international clinical studies. European ACCIS renal-tumor study

More recent evidence from the United Kingdom and Ireland reported:

97.8% overall survival at one year
92.5% overall survival at five years
94.8% five-year survival among children aged zero to four

The study included children and young people diagnosed between 2012 and 2022 through 20 principal childhood cancer treatment centres. UK and Ireland IMPORT study

These UK and Ireland results should not be presented as the current survival rate for every Northern European country. Contemporary, directly comparable Wilms tumor survival data remain less readily available for some Nordic and Baltic populations.

Wilms Tumor Mortality in Northern Europe

A single current Wilms tumor mortality rate covering all Northern European countries is not available. Mortality is usually expressed through overall or disease-specific survival rather than as an annual population death rate.

Historical five-year survival of 91% in Northern Europe corresponds to approximately nine deaths from any cause within five years per 100 children diagnosed during that historical study period.

Recent UK and Ireland five-year overall survival of 92.5% corresponds to approximately 7.5 deaths from any cause per 100 study patients within five years.

If approximately 140–160 children are diagnosed with Wilms tumor across Northern Europe annually and contemporary five-year survival is broadly between 90% and 93%, a planning model would suggest approximately 10–16 deaths within five years among each annual diagnosis cohort.

This is an inference rather than a confirmed regional death count.

Regional mortality comparisons are affected by:

Different study periods.
Small patient numbers in lower-population countries.
Overall versus disease-specific survival.
Different stage distributions.
Histological-risk differences.
Clinical-trial participation.
Registry coverage.
Length and completeness of follow-up.

Stage Distribution in Northern Europe

Comprehensive stage data using one standardized reporting system are not publicly available for every Northern European country. The most detailed recent regional evidence comes from the United Kingdom and Ireland IMPORT study.

Among 570 patients with unilateral Wilms tumor:

Stage / Patients / Proportion

Stage I / 216 / 37.9%
Stage II/ 106 / 18.6%
Stage III / 93 / 16.3%
Stage IV / 151 / 26.5%
Unknown / 4 / 0.7%

Overall:

419 patients, or 73.5%, had localized disease
151 patients, or 26.5%, had metastatic disease
A further 50 of the complete 620-patient cohort, or 8%, had bilateral disease

The researchers noted that children in the UK and Ireland had a higher proportion of advanced disease than children in several other European countries, including France and Germany.

The median tumor volume at diagnosis was approximately 595 cm³. After preoperative chemotherapy, it fell to approximately 228 cm³, although 28% of evaluable tumors remained at least 500 cm³.

These findings reinforce the continuing importance of earlier recognition and referral, even within healthcare systems that provide specialist pediatric oncology care.

UK and Ireland IMPORT study

Survival by Stage in the UK and Ireland

The IMPORT study reported five-year overall survival of:

Stage / Five-year overall survival

Stage I / 97.0%
Stage II / 93.8%
Stage III / 85.2%
Stage IV / 88.9%
Stage IV survival being numerically higher than Stage III does not indicate that metastatic disease is generally less serious. The difference may reflect patient numbers, histology, treatment intensity, metastatic response and statistical variation.

The broader SIOP Renal Tumour Study Group has reported approximate five-year survival of:

98% for Stage I
94% for Stage II
90% for Stage III
82% for Stage IV

These figures provide clinical context but should not be used to predict the outcome of an individual child.

Histological Risk and Northern European Outcomes

European treatment systems use histology, stage, tumor response and other factors to classify risk and determine postoperative treatment.

In the UK and Ireland IMPORT study, five-year overall survival was:

Histological risk / Five-year overall survival

Low risk / 100%
Intermediate risk / 95.2%
High risk / 74.6%

After adjusting for age, stage, sex and tumor volume, high-risk histology remained the most important adverse prognostic factor. The adjusted excess risk of death was approximately 10.8 times greater for high-risk histology than for low- or intermediate-risk tumors.

This finding supports Northern Europe’s continuing participation in molecular and pathological research intended to identify high-risk patients more accurately and develop better relapse-prevention strategies.

Wilms Tumor Treatment Systems in Northern Europe

Northern European children are generally treated at designated pediatric oncology centres rather than through general adult cancer services.

Treatment commonly follows or aligns with European SIOP principles, including:

Specialist imaging.
Multidisciplinary review.
Preoperative chemotherapy for most patients.
Delayed nephrectomy.
Central or expert pathology review.
Postoperative risk classification.
Risk-adapted chemotherapy.
Radiation therapy for selected patients.
Long-term follow-up.

In the UK and Ireland IMPORT cohort:

94% received preoperative chemotherapy
6% underwent immediate surgery

European protocols may use approximately four weeks of preoperative chemotherapy for localized disease and six weeks for metastatic disease, although the exact schedule depends on the protocol and diagnosis.

National health authorities remain responsible for approving and implementing treatment protocols, medicines and specialist-service arrangements.

National Healthcare Systems

Each Northern European country organizes pediatric oncology through its own healthcare system.

United Kingdom

Care is provided through the NHS systems of England, Scotland, Wales and Northern Ireland. Children with suspected cancer are referred to specialist principal treatment centres and associated pediatric oncology shared-care services.

Clinical research and professional coordination are supported by organizations including the Children’s Cancer and Leukaemia Group.

Ireland

Pediatric oncology is organized through the national health system and specialist childhood cancer services. Ireland has participated with the United Kingdom in renal-tumor research, including the IMPORT study, and subsequently adopted the SIOP–RTSG UMBRELLA framework.

Nordic countries

Denmark, Finland, Iceland, Norway and Sweden operate tax-funded national or regional healthcare systems. Pediatric oncology is concentrated within specialist university and children’s hospitals.

The Nordic model supports:

National cancer registration.
Shared clinical research.
Professional collaboration.
Population-based follow-up.
Long-term survivorship research.
Cross-border exchange of knowledge.

Baltic states

Estonia, Latvia and Lithuania organize pediatric oncology through their respective national health systems and specialist centres.

The Baltic states participate in wider European and Nordic–Baltic professional networks. However, differences in population size, specialist capacity and clinical-trial availability mean that regional collaboration remains particularly important for rare tumors.

SIOP Renal Tumour Study Group

The International Society of Paediatric Oncology Renal Tumour Study Group—SIOP–RTSG—provides one of the principal research and treatment frameworks used across Europe.

Its UMBRELLA protocol aims to:

Standardize diagnostic imaging.
Harmonize pathology.
Improve risk classification.
Validate molecular biomarkers.
Reduce treatment for lower-risk disease.
Improve treatment for high-risk disease.
Strengthen international data collection.
Support long-term outcome research.

The UMBRELLA framework is not a supranational law or health authority. Participating countries and centres implement it through national approvals, clinical governance and research structures.

SIOP–RTSG UMBRELLA protocol

Children’s Cancer and Leukaemia Group

The Children’s Cancer and Leukaemia Group supports childhood cancer research, professional coordination and family information in the United Kingdom and Ireland.

The UK and Ireland IMPORT study collected detailed information on Wilms tumor diagnosis, stage, tumor volume, histology, treatment and survival. Patients were treated through 20 principal treatment centres using a standardized risk-adapted approach.

The SIOP–RTSG UMBRELLA protocol replaced IMPORT in the United Kingdom from 2019 and subsequently in Ireland.

Current CCLG-supported kidney cancer research includes UMBRELLA PLUS, which is investigating more molecularly informed treatment and relapse-risk prediction.

CCLG UMBRELLA PLUS

Nordic Society of Paediatric Haematology and Oncology

The Nordic Society of Paediatric Haematology and Oncology—NOPHO—supports collaboration among pediatric oncology professionals across Nordic and Baltic countries.

NOPHO contributes to:

Shared clinical studies.
Treatment development.
Cancer-registry collaboration.
Professional education.
Outcome comparison.
Toxicity and late-effects research.
Cross-border knowledge sharing.

NOPHO does not replace national health authorities. Treatment remains governed by each country’s healthcare system, hospitals, ethical approvals and clinical policies.

Nordic and Baltic pediatric oncology research networks

ERN PaedCan and Cross-Border Expertise

The European Reference Network for Paediatric Cancer—ERN PaedCan—connects specialist pediatric oncology centres across the European Union and Norway.

ERN PaedCan includes:

79 full-member hospitals from 21 countries
11 affiliated hospitals from seven countries
Coverage extending across EU Member States and Norway

Its purpose is to reduce inequalities in access to pediatric cancer expertise. Healthcare professionals can use virtual tumor boards and cross-border consultation to discuss rare or complex cases.

Patients do not normally approach ERN PaedCan directly. Their treating healthcare professionals can seek expert input in accordance with national regulations and patient consent.

ERN PaedCan

The wider European Reference Network system included 1,606 specialist centres in 375 hospitals across 27 EU Member States and Norway as of October 2025.

European Commission: European Reference Networks

The United Kingdom’s post-EU relationship with European networks and cross-border healthcare differs from that of EU Member States and Norway. UK clinicians and researchers nevertheless continue to participate in international pediatric oncology research and professional collaboration through other mechanisms.

European Clinical-Practice Guidance

ERN PaedCan, SIOP Europe and European clinical-trial groups have developed European Standard Clinical Practice resources for childhood cancers.

These resources provide benchmarks for:

Diagnosis.
Imaging.
Pathology.
Treatment.
Supportive care.
Follow-up.
Referral to specialist expertise.

Their purpose is to improve consistency and reduce inequalities across Europe while recognizing that national implementation depends on local healthcare systems and available resources.

European pediatric cancer clinical-practice guidance

Wilms Tumor Research in Northern Europe

Northern European centres contribute to international research into:

Earlier diagnosis.
Tumor volume and treatment response.
Molecular biomarkers.
High-risk histology.
Metastatic disease.
Relapsed Wilms tumor.
Kidney-preserving surgery.
Reduction of radiation exposure.
Fertility and endocrine health.
Long-term kidney and heart health.
Subsequent cancers.
Survivor quality of life.

CCLG reports that approximately 1,000 children are diagnosed with Wilms tumor across Europe each year and that around 90% can be treated successfully with surgery, chemotherapy and radiotherapy when required.

UMBRELLA PLUS seeks to improve the use of molecular information in treatment selection and relapse-risk prediction.

CCLG childhood kidney cancer research

Cancer Registries and Data Quality

Northern Europe has well-established cancer-registration systems, but directly comparable Wilms tumor statistics are not published uniformly across all ten countries.

Registries and clinical studies may use different:

Age ranges.
Diagnostic classifications.
Treatment periods.
Survival definitions.
Stage definitions.
Follow-up periods.
National and regional coverage.

The UK and Ireland IMPORT study registered an estimated 80% of newly diagnosed Wilms tumor patients during its operating period. This level of coverage supports population-relevant analysis of stage, histology and outcomes.

WCF will distinguish between:

Registry-confirmed figures.
Published study findings.
Country-level estimates.
WCF modelled regional estimates.

Survivorship in Northern Europe

With five-year survival exceeding 90% in many Northern European patient groups, survivorship services are an increasingly important part of pediatric oncology.

Northern European follow-up systems may monitor:

Kidney function.
Blood pressure.
Heart and lung health.
Growth and puberty.
Fertility.
Endocrine health.
Learning and school participation.
Emotional well-being.
Subsequent cancers.
Transition into adult healthcare.

Services vary between countries and treatment centres. Some survivors are followed through dedicated late-effects clinics, while others transition to primary care, general pediatric services or adult specialists using a risk-based follow-up plan.

An international study included 2,893 British and 1,574 Nordic Wilms tumor survivors treated between 1960 and 2004. Among those who remained free of a subsequent solid tumor to age 15, the cumulative incidence of a secondary solid cancer by age 40 was approximately 6.7%.

Because the cohort included historical treatments, the risk for children receiving modern risk-adapted therapy may be different.

Secondary malignant neoplasms after Wilms tumor

Regional Differences and Remaining Priorities

Northern Europe generally has strong pediatric oncology outcomes, but continued improvement is needed.

Regional priorities include:

Diagnosing tumors at a smaller volume.
Reducing advanced-stage presentation.
Improving outcomes for high-risk histology.
Developing better relapse treatments.
Expanding molecular risk classification.
Preserving kidney function.
Reducing late effects.
Strengthening transition into adult care.
Ensuring equitable access to clinical trials.
Maintaining high-quality cancer registries.
Supporting smaller national pediatric oncology systems.

The small populations of Iceland and the Baltic states make international collaboration especially important because individual centres may treat relatively few cases of a rare childhood renal tumor.

WCF, WHO and the Global Initiative for Childhood Cancer

Through its partnership with the World Health Organization, the Wilms Cancer Foundation develops specialist educational literature supporting the objectives of the WHO Global Initiative for Childhood Cancer.

Although Northern European Wilms tumor survival already exceeds the GICC target of at least 60% global childhood cancer survival by 2030, the region’s experience can contribute to wider international improvements through:

Clinical research.
Cancer registration.
Professional education.
Standardized treatment.
Long-term follow-up.
International knowledge sharing.

WHO Global Initiative for Childhood Cancer

WCF’s Global Wilms Tumor Initiative™ in Northern Europe

Through WCF’s Global Wilms Tumor Initiative™ (GWTI), educational literature developed through its WHO partnership is adapted and made available across different countries and languages.

GWTI activity in Northern Europe includes:

Regional Wilms tumor information.
Country-specific resources.
Parent and caregiver education.
Healthcare-professional information.
Survivorship resources.
Translated literature as country pages develop.
Responsible country and organizational engagement.

The availability of WCF literature does not automatically mean WCF or WHO has a formal partnership with a national government, hospital or childhood cancer organization. Formal country-level relationships will be identified separately.

Explore Wilms Tumor by Country

United Kingdom

Explore Wilms tumour incidence, NHS diagnosis and referral, treatment through specialist childhood cancer centres, UK and Ireland research, stage-specific outcomes and survivorship support.

Read more about Wilms tumour diagnosis, treatment, research and family support in the United Kingdom.

Additional pages for Ireland, Denmark, Estonia, Finland, Iceland, Latvia, Lithuania, Norway and Sweden can be introduced as WCF’s Global Wilms Tumor Initiative™ expands.

References and Further Information

Regional incidence and survival

Malignant renal tumours: incidence and survival in European children
European ACCIS analysis of more than 5,000 childhood renal tumors, including incidence, bilateral disease and Northern European survival.

International population-based study of childhood renal-tumor incidence
Analysis of 15,320 childhood renal tumors reported by 163 cancer registries.

UK and Ireland outcomes

Survival for children diagnosed with Wilms tumour in the UK and Ireland, 2012–2022
IMPORT study reporting annual diagnoses, stage distribution, histological risk and survival.

UCL Renal Tumours and Childhood Cancer Outcomes Group
Information about IMPORT, UMBRELLA and research into renal-tumor risk classification.

Treatment and clinical research

SIOP–RTSG UMBRELLA protocol
International guidance relating to pathology, molecular research and risk-adapted treatment.

CCLG UMBRELLA PLUS
Research into molecularly guided childhood kidney cancer treatment.

Regional professional networks

Nordic and Baltic pediatric oncology research networks
Information about NOPHO and related research infrastructure.

ERN PaedCan
European Reference Network connecting specialist pediatric oncology centres.

European Commission: European Reference Networks
Official information about cross-border networks for rare and complex conditions.

European pediatric cancer clinical-practice guidance
Information about European Standard Clinical Practice resources.

Survivorship

Secondary malignant neoplasms after Wilms tumor
International study involving British, Nordic and North American survivors.

Global childhood cancer

WHO Global Initiative for Childhood Cancer
Official information about global childhood cancer survival and healthcare-system goals.

Medical, Statistical and Partnership Disclaimer

The information on this page is provided for educational and informational purposes only. It is not intended to replace professional medical advice, diagnosis, treatment or follow-up recommendations. Families should consult qualified healthcare professionals familiar with the child’s individual diagnosis, stage, histology, treatment response and health.

Statistics describe groups of patients treated during particular periods and cannot predict an individual child’s outcome. Figures may vary according to country, study population, treatment protocol, stage definition, follow-up period and data quality.

Northern European case and mortality figures identified as WCF estimates are modelled planning figures derived from published incidence and survival evidence. They are not confirmed regional registry totals.

References to WHO, GICC, SIOP–RTSG, CCLG, NOPHO, ERN PaedCan, national healthcare systems or research organizations provide medical, policy and programme context. They do not imply that those organizations have reviewed or endorsed this page.

Through its partnership with the World Health Organization, WCF develops educational literature supporting the objectives of the WHO Global Initiative for Childhood Cancer. Through WCF’s Global Wilms Tumor Initiative™, these resources are adapted and made available internationally. Their availability in a country does not automatically indicate a formal partnership with a local government, hospital or organization.

What This Means for Parents and Caregivers

For parents and caregivers of a child diagnosed with Wilms tumor in Northern Europe, it can be reassuring to know that the region benefits from highly developed pediatric healthcare systems, specialist childhood cancer centres, established multidisciplinary care, and close participation in European and international childhood cancer research networks.

Countries across Northern Europe contribute to the wider European pediatric oncology community, where international cooperation has played an important role in improving the diagnosis and treatment of Wilms tumor (nephroblastoma). Many children are treated within national childhood cancer programmes or specialist centres that participate in European clinical networks and use evidence-based approaches informed by organisations such as the International Society of Paediatric Oncology Renal Tumour Study Group (SIOP-RTSG).

However, Northern Europe is not a single healthcare system. Referral pathways, treatment centres, clinical trial availability, supportive services, and long-term follow-up arrangements can differ between countries. Your child's individual treatment will also depend upon the characteristics of their Wilms tumor and the recommendations of their specialist pediatric oncology team.

Your Child Will Usually Be Cared for by a Specialist Team

Wilms tumor is a rare pediatric kidney cancer and requires coordinated care from healthcare professionals with experience in childhood oncology and renal tumors.

Depending on your child's diagnosis and treatment, their multidisciplinary team may include:

Pediatric oncologists.
Pediatric surgeons.
Radiologists.
Pediatric pathologists.
Radiation oncologists.
Nephrologists and kidney specialists.
Specialist oncology nurses.
Pharmacists.
Psychologists and psychosocial professionals.
Dietitians, physiotherapists, and other allied healthcare professionals.
Survivorship and late-effects specialists.

This multidisciplinary approach is particularly important because Wilms tumor treatment involves much more than removing a kidney tumor. Decisions concerning chemotherapy, surgery, radiation therapy, pathology, risk classification, kidney preservation, supportive care, and long-term follow-up need to be carefully coordinated around the individual child.

Treatment May Follow a SIOP-Based Wilms Tumor Approach

Many European countries participate in or are influenced by treatment and research developed through SIOP-RTSG, which has established internationally collaborative approaches for childhood renal tumors. The SIOP-RTSG UMBRELLA framework includes recommendations for localized, metastatic, bilateral, and relapsed Wilms tumor and was developed through multidisciplinary international expertise.

One characteristic parents may encounter is the use of chemotherapy before surgery, which is an important feature of the SIOP approach to Wilms tumor.

Depending upon your child's diagnosis, treatment may include:

Pre-operative chemotherapy.
Surgery to remove the kidney tumor.
Detailed pathology and risk classification.
Post-operative chemotherapy.
Radiation therapy for selected children.
More intensive treatment for some high-risk tumors.
Specialist approaches for bilateral Wilms tumor.
Additional treatment for metastatic or relapsed disease.
Structured surveillance and long-term follow-up after treatment.

Not every child requires every treatment. Wilms tumor therapy is increasingly risk-adapted, with treatment intensity determined by factors such as disease stage, histology, response to pre-operative therapy, tumor biology where relevant, and the individual child's circumstances.

Ask Which Treatment Protocol Your Child Is Following

Parents sometimes discover online that Wilms tumor is treated differently in Europe and North America. This can understandably create confusion.

Different international research groups have developed highly successful approaches to treating Wilms tumor. European treatment has historically been strongly influenced by SIOP protocols, while North American treatment has been developed principally through approaches associated with the Children's Oncology Group and its predecessors.

A difference in treatment sequence does not automatically mean that one approach is better than another.

Useful questions for your child's medical team include:

Which Wilms tumor protocol is my child following?
Why was this treatment approach recommended?
What stage and risk group is my child's tumor?
What did the imaging show?
Will chemotherapy be given before surgery?
What type of surgery is planned?
How will the pathology results affect treatment?
Will my child require radiation therapy?
Is my child's case being reviewed by a specialist renal tumor multidisciplinary team?
Is a clinical study or trial relevant to my child?

Understanding the reasoning behind treatment can help parents participate more confidently in discussions with their child's healthcare team.

Outcomes Are Encouraging, but Every Child Is Different

Modern Wilms tumor treatment has achieved high survival overall, with contemporary treatment regimens combining chemotherapy and surgery and, for selected children, radiation therapy. Published SIOP-Europe guidance notes survival of around 90% overall, although outcomes differ substantially between disease groups.

For an individual child, prognosis can be influenced by:

Stage at diagnosis.
Tumor histology.
Whether disease has spread beyond the kidney.
Whether one or both kidneys are affected.
Response to initial treatment.
Tumor biology and molecular characteristics where clinically relevant.
Whether the disease is newly diagnosed or relapsed.
The child's overall health and individual treatment circumstances.

Children with localised, favourable-risk disease may have a very different outlook from children with high-risk histology, metastatic disease, bilateral tumors, or relapsed Wilms tumor.

Population statistics therefore cannot predict exactly what will happen to an individual child. Your child's pediatric oncology team can provide the most meaningful interpretation of prognosis based upon their specific diagnosis.

Northern European Care Is Connected to a Wider European Network

One important advantage for families is that pediatric oncology increasingly operates through national and international networks rather than individual hospitals working in isolation.

For rare childhood cancers such as Wilms tumor, this is particularly valuable. International collaboration allows specialists to combine experience from larger numbers of children, develop common treatment approaches, conduct clinical research, establish pathology standards, and investigate biological markers that may eventually allow treatment to become even more precisely tailored.

The SIOP-RTSG UMBRELLA programme, for example, was specifically developed to promote international collaboration and harmonisation in childhood renal tumor treatment and research.

For families, this means that even though your child may be treated at a hospital within your own country, the knowledge informing their care may reflect decades of research involving specialists and children from many countries.

Long-Term Health Matters as Much as Completing Treatment

For many children, successful treatment of Wilms tumor is followed by decades of life after cancer. This makes survivorship and long-term follow-up an important part of pediatric cancer care.

Follow-up requirements vary according to the treatment a child received, but healthcare teams may monitor:

Remaining kidney function.
Blood pressure.
Heart health following certain chemotherapy exposures.
Growth and development.
Fertility and reproductive health.
Endocrine health.
Effects associated with radiation therapy where applicable.
Emotional and psychological wellbeing.
Education and school reintegration.
Physical activity and healthy lifestyle.
Other potential late effects of childhood cancer treatment.

European Standards of Care specifically recognise survivorship, psychosocial support, rehabilitation and long-term care as important components of comprehensive childhood cancer services.

Ask your child's healthcare team what follow-up will be required after treatment and whether your child will eventually receive a treatment summary or survivorship care plan.

Your Child's Kidney Health Will Need Continued Attention

Many children treated for unilateral Wilms tumor live with one functioning kidney following nephrectomy. Most can lead active lives, but protecting long-term renal health remains important.

Your child's medical team may therefore monitor kidney function and blood pressure during treatment and survivorship. Children with bilateral Wilms tumor, underlying genetic conditions, pre-existing renal abnormalities, or particular treatment exposures may require additional specialist follow-up.

Parents can ask:

How much kidney function does my child currently have?
How frequently should kidney function be monitored?
How often should blood pressure be checked?
Does my child need nephrology follow-up?
Are there medicines or activities we should discuss with the medical team?
What monitoring will be needed in adulthood?

Establishing good long-term health habits during childhood can become an important part of survivorship.

Family and Psychosocial Support Are Part of Cancer Care

A childhood cancer diagnosis affects the entire family. Parents may experience anxiety, financial pressure, disrupted employment, travel requirements, and uncertainty about the future, while siblings can also experience significant changes to family life.

Children themselves may require support with fear, treatment-related anxiety, changes in appearance, school absence, friendships, physical recovery, or returning to everyday life after treatment.

Modern European pediatric oncology standards increasingly recognise psychological, social, educational, and rehabilitation support as part of comprehensive cancer care, rather than treating these needs as separate from medical treatment.

Ask your treatment centre about:

Psychology or counselling.
Social work support.
School and educational assistance.
Support for siblings.
Parent organisations and peer support.
Financial or practical assistance.
Rehabilitation services.
Survivorship programmes.

Seeking these services is a normal part of supporting a child and family through cancer treatment.

Access Can Still Differ Across Northern Europe

Northern Europe generally benefits from sophisticated healthcare infrastructure, but parents should not assume that every child has access to exactly the same services.

Specialist centres, national referral systems, clinical trials, advanced radiotherapy, genetic services, fertility preservation, psychosocial care, rehabilitation, and survivorship programmes can vary between countries and between treatment centres.

European childhood cancer organisations continue to work specifically on reducing these inequalities. Revised European Standards of Care aim to improve equitable access to high-quality multidisciplinary treatment, supportive care, psychosocial services, rehabilitation, survivorship care, and innovative therapies regardless of where a child lives.

If your child has a particularly rare, high-risk, bilateral, or relapsed Wilms tumor, it is reasonable to ask whether their case should receive additional national or international specialist review.

Parents Are Important Partners in Their Child's Care

You do not need to understand every aspect of pediatric oncology, but becoming familiar with your child's diagnosis can make the treatment journey easier to navigate.

Where possible, keep a record of important information including:

Exact diagnosis and pathology.
Wilms tumor stage and risk classification.
Treatment protocol.
Chemotherapy medicines and cumulative doses.
Surgical procedures.
Radiation therapy details, if applicable.
Important imaging reports.
Genetic testing, if undertaken.
Treatment complications.
End-of-treatment summary.
Long-term follow-up recommendations.

This information can become particularly valuable as your child grows older and eventually transitions from pediatric oncology into adult healthcare.

Northern Europe Is Part of the International Effort to Improve Wilms Tumor Care

One of the most important messages for families is that progress in Wilms tumor has been built through international cooperation.

Because Wilms tumor is rare, researchers and healthcare professionals need to work across hospitals and national borders to study sufficiently large groups of children, understand why some tumors behave differently, identify children at greater risk of relapse, and determine when treatment can safely be reduced to minimise long-term side effects.

Current international research continues to investigate better risk stratification, molecular markers, treatment reduction for appropriate children, improved therapies for high-risk and relapsed disease, and ways of protecting survivors from unnecessary long-term treatment effects. The SIOP-RTSG UMBRELLA framework was explicitly designed to advance this international harmonisation and research.

For parents and caregivers in Northern Europe, this means your child's care exists within a much larger international community of pediatric oncologists, surgeons, researchers, nurses, patient organisations, and childhood cancer advocates continually working to improve Wilms tumor treatment.

The goal is increasingly not simply to help more children survive Wilms tumor, but to ensure that survivors grow into adulthood with the best possible kidney health, physical health, emotional wellbeing, fertility, education, quality of life, and long-term future.

Frequently Asked Questions

About Wilms Tumor in Northern Europe

How many children develop Wilms tumor in Northern Europe each year?

Applying published European incidence rates to the regional child population suggests approximately 140–160 annual diagnoses. This is a WCF modelled estimate rather than a confirmed registry total.

Which Northern European country records the most cases?

The United Kingdom’s larger population means it accounts for a substantial proportion of cases. Approximately 83 children are diagnosed with Wilms tumor in the UK annually.

What is the Northern European survival rate?

Historical European registry data reported approximately 91% five-year survival in Northern Europe. More recent UK and Ireland evidence reported 92.5% five-year overall survival.

What is the mortality rate?

No single current mortality rate covers all Northern European countries. UK and Ireland five-year survival of 92.5% corresponds to approximately 7.5 deaths from any cause per 100 study patients within five years.

What proportion of cases are metastatic?

In the UK and Ireland IMPORT study, 26.5% of unilateral tumors were classified as Stage IV or metastatic. This should not be assumed to represent every Northern European country.

What proportion affect both kidneys?

Approximately 7%–8% of cases in the cited European and UK/Ireland evidence involved both kidneys.

What is the survival rate for Stage I disease?

The UK and Ireland study reported approximately 97.0% five-year overall survival for Stage I Wilms tumor.

What is the survival rate for Stage IV disease?

The study reported approximately 88.9% five-year overall survival for Stage IV disease. Individual outcomes depend on histology, metastatic response and other risk factors.

Which treatment framework is used?

Many Northern European centres use or align with the SIOP–RTSG approach, usually involving preoperative chemotherapy followed by nephrectomy and risk-adapted postoperative treatment.

What is NOPHO?

NOPHO is the Nordic Society of Paediatric Haematology and Oncology. It supports professional, clinical and research collaboration across Nordic and Baltic pediatric oncology.

What is ERN PaedCan?

ERN PaedCan is the European Reference Network for Paediatric Cancer. It enables specialist consultation and knowledge sharing across participating European healthcare systems.

Does WCF have a partner in every Northern European country?

No. WCF may provide educational resources without having a formal local partner. Any formal country partnership will be identified separately.

Explore Wilms Tumor by Region & Country

Europe (Regional)

Explore Wilms tumor incidence, staging, treatment systems, survival outcomes and paediatric kidney cancer research across Northern, Western, Southern and Eastern Europe.

Northern Europe (Regional)

Explore Wilms tumor incidence, stage at diagnosis, specialist treatment, survival and childhood kidney cancer research across Northern Europe, including the United Kingdom, Ireland and the Nordic countries.

Western Europe (Regional)

Explore Wilms tumor incidence, European treatment approaches, survival, research and country resources for Western Europe, including France and Germany.

Southern Europe (Regional)

Learn about childhood kidney cancer incidence, diagnosis, treatment, survival, survivorship and educational resources across Southern Europe, including Spain and Italy.

Read more about Wilms tumor statistics, treatment systems, clinical research, survival outcomes and family resources across Southern Europe.

North America (Regional)

Explore Wilms tumor incidence, diagnosis, treatment protocols, clinical research, survival and survivorship resources for Canada and the United States.

Read more about Wilms tumor treatment, clinical trials, survival outcomes, long-term follow-up and childhood kidney cancer care in North America.

Central America (Regional)

Learn about Wilms tumor incidence, diagnostic access, treatment systems, continuity of care and Spanish-language family resources across Central America, beginning with Mexico.

Read more about Wilms tumor diagnosis, treatment access, survival outcomes, healthcare inequalities and childhood kidney cancer resources in Central America.

South America (Regional)

Explore Wilms tumor incidence, regional healthcare inequalities, paediatric oncology access, treatment completion, survival and Spanish-language resources, beginning with Argentina.

Read more about Wilms tumor statistics, diagnostic and treatment access, survival inequalities, clinical collaboration and family resources in South America.

Africa (Regional)

Explore Wilms tumor incidence, symptom awareness, diagnostic access, specialist treatment, treatment abandonment, survival inequalities and family resources across Africa.

Read more about the burden of Wilms tumor, paediatric oncology capacity, treatment completion, survival outcomes and childhood kidney cancer care across Africa.

Southern Africa (Regional)

Learn about Wilms tumor symptom awareness, diagnosis, specialist treatment, treatment completion, survival and family resources across Southern Africa, including South Africa.

Read more about Wilms tumor incidence, diagnostic access, paediatric oncology treatment, survival and childhood kidney cancer care in Southern Africa.

Northern Africa (Regional)

Explore Wilms tumor incidence, healthcare access, diagnostic capacity, treatment challenges, survival and family resources across Northern Africa, including Sudan.

Read more about Wilms tumor statistics, specialist treatment access, survival inequalities and childhood kidney cancer support in Northern Africa.

Asia (Regional)

Explore Wilms tumor incidence, diagnosis, treatment systems, survival, research and healthcare inequalities across East Asia, South Asia and other Asian regions.

Read more about childhood kidney cancer burden, paediatric oncology access, treatment completion, clinical research and Wilms tumor resources across Asia.

East Asia (Regional)

Learn about Wilms tumor incidence, treatment systems, clinical research, survival and country-language educational resources for East Asia, including China and South Korea.

Read more about Wilms tumor statistics, paediatric oncology treatment, research, survival and childhood kidney cancer resources in East Asia.

China (Country)

Explore Wilms tumor incidence, diagnosis, treatment systems, clinical research, survival and Chinese-language educational resources for children and families in China.

Read more about Wilms tumor treatment, paediatric oncology care, survival outcomes, research and childhood kidney cancer resources in China.

South Korea (Country)

Learn about Wilms tumor incidence, specialist treatment, clinical research, survival and Korean-language educational resources for children, families and healthcare professionals in South Korea.

Read more about Wilms tumor diagnosis, paediatric oncology treatment, research, survivorship and childhood kidney cancer resources in South Korea.

South Asia (Regional)

Explore childhood kidney cancer burden, diagnostic and treatment access, survival inequalities, family support and country resources across South Asia, including India.

Read more about Wilms tumor incidence, diagnosis, treatment systems, treatment completion, survival and family resources in South Asia.

Middle East (Regional)

Learn about Wilms tumor incidence, diagnostic and treatment access, paediatric oncology capacity, healthcare inequalities and Persian- and Arabic-language educational needs across the Middle East.

Read more about Wilms tumor statistics, treatment systems, survival inequalities, clinical collaboration and family support across the Middle East.

Iran (Country)

Learn about Wilms tumor diagnosis, treatment, survivorship and Persian-language educational resources in Iran, including the WCF’s partnership with MAHAK.

Read more about Wilms tumor care, paediatric oncology services, family support and WCF and MAHAK collaborative initiatives in Iran.

Regional & Country Hub

Parent & Caregiver Support